Rallybio Corporaton (RLYB)

$0.66 -0.02 (-2.84%)
Market Cap 28.95M
Revenue (ttm) 640,000.00
Net Income (ttm) -57.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,028.13%
Debt to Equity Ratio 0.00
Volume 198,400
Avg Vol 181,576
Day's Range N/A - N/A
Shares Out 42.24M
Stochastic %K 13%
Beta -1.05
Analysts Sell
Price Target $1.00

Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-tar...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 859 3820
Address:
234 Church Street, Suite 1020, New Haven, United States
estatebuyersmia
estatebuyersmia Jan. 16 at 11:18 PM
$RLYB WHAT A DUMB COMMENT, IF THE NEWS IS GOOD IT WILL RERATE SO WHATS THE POINT OF POSTING THIS.. IT ADDS NOTHING TO THIS BOARD.. YOURE LIKE ALL THE OTHER BEARS, YOU POST BS JUST TO HEAR YOURSELF TALK. IF YOU HAVE SOMETHING WORTHWHILE THAN SHARE IT OTHERWISE GO AWAY AND HIDE UNDER A ROCK.
0 · Reply
BiotechValues
BiotechValues Jan. 16 at 9:36 PM
$RLYB pumpers desperate despite stock running down into reverse split announcement. This has a lot of room to fall if data is "meh" and reverse split comes..
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Jan. 16 at 9:13 PM
Give me that birthday news :D $RLYB
0 · Reply
BiotechValues
BiotechValues Jan. 16 at 8:54 PM
$RLYB I'm guessing you know who is selling out...
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 16 at 5:10 PM
$RLYB The way I see it.. Rallybio 116 is going to work or they wouldnt have sold off their other program to raise capital to keep themselves afloat. These guys are very smart and run a very tight ship. Their workforce is lean which tells me that they know how to manage expenses.
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 16 at 5:06 PM
$RLYB For me silence always is a precursor to good news... If it were bad they would have no need to hold back releasing data.
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 16 at 12:09 AM
$RLYB WOW, IF YOU CANT BE PATIENT THAN JUST SELL YOUR STOCK....
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Jan. 15 at 7:08 PM
$RLYB - It has now been approximately four weeks since cohort 2 finished dosing. Continued silence by the company (remember in Sept. they PR'd completing cohort 1 dosing and announced high level efficacy/safety). No 2026 slide deck. No website updates or LinkedIn posts by management. IR is ignoring subsequent emails. The "Grand Finale" should be any moment now.
2 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 14 at 6:23 PM
$RLYB Directly from Investor Relation last Friday "Because RLYB116 is a long-acting molecule, we have to continue long term safety and efficacy follow up and various blood tests have to be finalized. Please rest assured we remain fully committed to RLYB116 and are looking forward to sharing the data as soon as we are in a position to do so." They had the final patient's data back in mid-Dec so they've already seen the topline data internally. A response like this to me seems more like an excuse to delay PR because they are working on some sort of M&A negotiation. News very soon IMO.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 13 at 3:30 PM
$RLYB more
0 · Reply
Latest News on RLYB
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 8:00 AM EST - 2 months ago

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Sep 25, 2025, 8:00 AM EDT - 4 months ago

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Sep 3, 2025, 8:00 AM EDT - 4 months ago

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Jul 8, 2025, 9:44 AM EDT - 6 months ago

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Jul 8, 2025, 8:00 AM EDT - 6 months ago

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Jun 12, 2025, 8:00 AM EDT - 7 months ago

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 9 months ago

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 9 months ago

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Apr 8, 2025, 1:01 PM EDT - 10 months ago

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Apr 8, 2025, 8:00 AM EDT - 10 months ago

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 13, 2025, 8:00 AM EDT - 11 months ago

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 8:00 AM EST - 11 months ago

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Feb 11, 2025, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Jan 10, 2025, 8:00 AM EST - 1 year ago

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Dec 2, 2024, 8:00 AM EST - 1 year ago

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Nov 27, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Nov 25, 2024, 8:00 AM EST - 1 year ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Nov 21, 2024, 8:00 AM EST - 1 year ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 7, 2024, 8:00 AM EST - 1 year ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Sep 9, 2024, 5:15 PM EDT - 1 year ago

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis

National Vision Releases 2023 Sustainability Report

Aug 27, 2024, 8:00 AM EDT - 1 year ago

National Vision Releases 2023 Sustainability Report

ACNT

Rallybio to Present at Upcoming Investor Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at Upcoming Investor Conferences

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Apr 17, 2024, 4:01 PM EDT - 1 year ago

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Apr 10, 2024, 4:01 PM EDT - 1 year ago

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Apr 1, 2024, 10:05 AM EDT - 1 year ago

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:00 AM EST - 2 years ago

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Feb 6, 2024, 8:00 AM EST - 2 years ago

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Jan 4, 2024, 8:00 AM EST - 2 years ago

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Dec 20, 2023, 8:00 AM EST - 2 years ago

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Dec 9, 2023, 12:00 PM EST - 2 years ago

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Nov 28, 2023, 7:00 AM EST - 2 years ago

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 8:00 AM EST - 2 years ago

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Rallybio to Present at Upcoming Investor Conferences in November

Nov 8, 2023, 8:00 AM EST - 2 years ago

Rallybio to Present at Upcoming Investor Conferences in November

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Rallybio to Present at the JonesTrading 2023 Healthcare Summit

Rallybio: Gearing Up To Be An Opportunity

Sep 15, 2023, 5:15 PM EDT - 2 years ago

Rallybio: Gearing Up To Be An Opportunity

estatebuyersmia
estatebuyersmia Jan. 16 at 11:18 PM
$RLYB WHAT A DUMB COMMENT, IF THE NEWS IS GOOD IT WILL RERATE SO WHATS THE POINT OF POSTING THIS.. IT ADDS NOTHING TO THIS BOARD.. YOURE LIKE ALL THE OTHER BEARS, YOU POST BS JUST TO HEAR YOURSELF TALK. IF YOU HAVE SOMETHING WORTHWHILE THAN SHARE IT OTHERWISE GO AWAY AND HIDE UNDER A ROCK.
0 · Reply
BiotechValues
BiotechValues Jan. 16 at 9:36 PM
$RLYB pumpers desperate despite stock running down into reverse split announcement. This has a lot of room to fall if data is "meh" and reverse split comes..
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Jan. 16 at 9:13 PM
Give me that birthday news :D $RLYB
0 · Reply
BiotechValues
BiotechValues Jan. 16 at 8:54 PM
$RLYB I'm guessing you know who is selling out...
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 16 at 5:10 PM
$RLYB The way I see it.. Rallybio 116 is going to work or they wouldnt have sold off their other program to raise capital to keep themselves afloat. These guys are very smart and run a very tight ship. Their workforce is lean which tells me that they know how to manage expenses.
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 16 at 5:06 PM
$RLYB For me silence always is a precursor to good news... If it were bad they would have no need to hold back releasing data.
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 16 at 12:09 AM
$RLYB WOW, IF YOU CANT BE PATIENT THAN JUST SELL YOUR STOCK....
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Jan. 15 at 7:08 PM
$RLYB - It has now been approximately four weeks since cohort 2 finished dosing. Continued silence by the company (remember in Sept. they PR'd completing cohort 1 dosing and announced high level efficacy/safety). No 2026 slide deck. No website updates or LinkedIn posts by management. IR is ignoring subsequent emails. The "Grand Finale" should be any moment now.
2 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 14 at 6:23 PM
$RLYB Directly from Investor Relation last Friday "Because RLYB116 is a long-acting molecule, we have to continue long term safety and efficacy follow up and various blood tests have to be finalized. Please rest assured we remain fully committed to RLYB116 and are looking forward to sharing the data as soon as we are in a position to do so." They had the final patient's data back in mid-Dec so they've already seen the topline data internally. A response like this to me seems more like an excuse to delay PR because they are working on some sort of M&A negotiation. News very soon IMO.
1 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 13 at 3:30 PM
$RLYB more
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 12 at 6:30 PM
$RLYB NOTHING IS GOING ON, THEY WONT RELEASE UNTIL AFTER THE REVERSE SPLIT VOTE DUE TO CORPORATE COMPLIANCE. THIS IS NORMAL AND AVOIDS LAWSUITS.
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 12 at 4:37 PM
$RLYB No corporate update PR like every other year first week of January. Something is definitely going on behind the scenes. Company is in quiet period.
1 · Reply
joe77w
joe77w Jan. 10 at 12:58 PM
$RLYB excellent
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Jan. 9 at 10:52 PM
$RLYB - Looks like some big things brewing. We know the data is "good" at least. Still think it's tied to M&A. Previous guidance was never about waiting for LT safety.
1 · Reply
estatebuyersmia
estatebuyersmia Jan. 9 at 7:03 PM
$RLYB I LOVE THIS COMPANY BUT IT IS HIGH RISK. THERE IS NO GUARANTEE THAT POSITIVE DATA RERATES THE STOCK, NONE..... IT MAY BUT IT MAY NOT AND THAN THE WAIT BEGINS ON A MUCH SMALLER FLOAT. THIS IS A GREAT COMPANY WITH GREAT MANAGEMENT WITH SERIOUS SCIENCE HOWEVER THEY HAVE STUMBLED AND NEED TO RECOVER. THAT RECOVERY COULD HAPPEN BUT ITS RISKY AT BEST.
1 · Reply
vinkush1
vinkush1 Jan. 9 at 6:59 PM
$RLYB when is the R/S meeting I can’t find the exact date 😅
1 · Reply
estatebuyersmia
estatebuyersmia Jan. 9 at 6:54 PM
$RLYB WHY WAITING UNTIL AFTER THE VOTE TO RELEASE DATA MAKES MORE SENSE
0 · Reply
skyrockets_Inc
skyrockets_Inc Jan. 9 at 6:16 PM
$RLYB What we do know is every year since 2022, by the first week of Jan they always released PR on 'Previous years Accomplishments and Anticipated New Year Milestones'. That PR should have come out by today to keep in line with the last 5 years trends. No PR. They are definitely in a quiet period . Something is being worked on behind the scenes IMO and major news hopefully coming soon :)
1 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 11:05 PM
$RLYB DATA WONT BE RELEASED UNTIL AFTER THE RS VOTE....
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 10:06 PM
$RLYB THIS STOCK IS TOTALLY ILLIQUID, NO BUYERS, NO SELLERS, HARD TO GET INTO, HARD TO GET OUT OF BUT THERE IS A CHANCE THAT THE DATA CAN BOOST LIQUIDITY BUT IT MAY ONLY DO THAT FOR A MOMENT AND THAN THE STOCK MAY NOT RERATE. THATS WHAT YOURE LOOKING AT. EVERYTHING ELSE IS SPECULATION HERE. IAM HOPING FOR A RERATE BUT NOTHING IS GUARANTEED. MANAGEMENT IS GREAT, THE BOARD IS GREAT, EVEN THE SCIENCE LOOKS PROMISING SO IAM HOPING FOR THE BEST.
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 10:01 PM
$RLYB THE TRUTH
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 8 at 9:58 PM
$RLYB SILENCE AND ILLIQUIDITY MAKE PEOPLE INVENT CERTAINTY WHEN THE BEST THING TO DO IS NOT SPECULATE AND WAIT FOR AN OUTCOME THAT MAY OR MAY NOT VALIDATE YOUR INVESTMENT.
0 · Reply